The US OTC drug industry and the Food and Drug Administration could look back on 2019 as a year that started with great promise but ended with little to show for products that expanded the market and regulatory milestones that made more expansion more likely.
Exhibit A for the sector’s 2019 performance could be GlaxoSmithKline PLC receiving a Complete Response letter from the FDA on its proposal to market the first mouth spray nicotine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?